Literature DB >> 2813664

Development of the Clozaril Patient Management System.

B Bastani1, L D Alphs, H Y Meltzer.   

Abstract

The Clozaril Patient Management System (CPMS) has been developed to provide a 100% fail-safe system for monitoring white blood cell counts (WBCs) in patients being treated with clozapine (Clozaril/Leponex) in the United States and to provide comprehensive data collection on the incidence and development of agranulocytosis. CPMS provides a case administrator and a registered pharmacist. Their role is to support the physician by facilitating the determination of WBC's at a national laboratory and by distributing clozapine to the patient. Specific tasks of the case administrator include: keeping track of outpatient phlebotomy appointments, following up missed appointments, ensuring that WBCs are obtained and analyzed weekly by the national laboratory, following up the results of these tests, providing liason with the pharmacy, maintaining a data base for all patients receiving clozapine and conveying these data to the physician. Initial experience with this program in Cleveland is described in this paper. The characteristics of patients enrolled in CPMS, satisfaction with the program and its success in meeting predetermined objectives are described. Experience with 31 patients in this outpatient setting suggests that CPMS can be an effective, reliable system for assisting in blood monitoring of patients being treated with clozapine.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2813664     DOI: 10.1007/bf00442576

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  3 in total

Review 1.  Leponex--associated granulocytopenia: a review of the situation.

Authors:  P Krupp; P Barnes
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report.

Authors:  H Y Meltzer; B Bastani; K Y Kwon; L F Ramirez; S Burnett; J Sharpe
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09
  3 in total
  4 in total

Review 1.  Drug-induced myelosuppression : diagnosis and management.

Authors:  Peter J Carey
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Making decisions about benefits and harms of medicines.

Authors:  Trisha Greenhalgh; Olga Kostopoulou; Clare Harries
Journal:  BMJ       Date:  2004-07-03

3.  Clozapine: an appraisal of its pharmacoeconomic benefits in the treatment of schizophrenia.

Authors:  A Fitton; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-08       Impact factor: 4.981

Review 4.  When should clozapine be initiated in schizophrenia?: Some arguments for and against earlier use of clozapine.

Authors:  Robert Kerwin
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.